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for plasma cholesterol, 7-de- (SLO), characterized by a number of birth defects affect-
hydrocholesterol (7-DHC), and 8-dehydrocholesterol (8- ing nearly every organ system.'
DHC) are invaluable for making the correct diagnosis in retarded, have a growth disorder, and show failure to
patients with the Smith-Lemli-Opitz syndrome (SLO) thrive. Both dysmorphic facial signs (microcephaly, pala-
and for biochemical monitoring of these patients during toschizis, cataracts, ptosis, micrognathia) and limb abnor-
therapy. The enzymatic method for cholesterol measure- malities (syndactyly of the second and third toe, polydac-
ment based on cholesterol oxidase gives falsely high tyly) occur in the patients. Genital disorders, hypospadia,
values for plasma cholesterol in samples from patients and cryptorchidism have been described. The syndrome
with SLO. Both 7-DHC and 8-DHC contribute substan- is estimated to be among the most common autosomal
tially to the test result, given that they are accepted recessive disorders among Caucasians, its prevalence
1:20 000 births [2J. A possible abnormality ofof cholesterol oxidase. All cholesterol meth-
ods making use of this enzyme are expected to give steroid secretion was first postulated by Chesalow et al. 
unreliable results with plasma samples from SLO pa- (31. Since then, Irons et al. have shown that SLO is caused 
tients. found with these methods by a defect in the cholesterol biosynthesis pathway [4, 5]. 
may be low-normal in individual cases with SLO. There- Patients have decreased concentrations of cholesterol in 
fore, other techniques for measuring cholesterol, 7-DHC, plasma and increased concentrations of the
and 8-DHC, e.g., gas chromatography, should be used for 7-dehydrocholesterol 3/3' 7-DHC)
diagnosing these patients and for follow-up during ther- and its isomer 8-dehydrocholesterol (cholesta-5,8-dien-
apy. However, a normal value for plasma cholesterol, as 3 0 8-DHC) in plasma, erythrocytes, skin
obtained by gas chromatography, does not exclude SLO. fibroblasts, amnio tic fluid, and various tissues [4 - 8 ]
The diagnosis should always be confirmed or excluded by ings that suggest a block in reduction of the C-7
testing for the presence of high concentrations of 7-DHC double bond ¡4, 51. Recently, those researchers confirmed
and 8-DHC in plasma. We found that one patient with a
severe form of the disease had a plasma cholesterol con­
centration of 20 fimol/L—to our knowledge, the lowest 
value ever recorded in a human being.
that the enzyme defect involved the 7-dehydrocholester- 
oI-A7-reductase in liver microsomes 19J.
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The aim of our study was to evaluate the reliability of 
the standard enzymatic assay (based on cholesterol oxi-
dase) for measuring plasma cholesterol in samples from
Because te
metabolism * gas e
en/vm«vtk assays * analytical error
7-DHC in plasma is not widely available, clinicians may
to use the presence of low concentrations of plasma
SLO as a first step towards
et al. HI described a syndrome, now confirming the diagnosis. Furthermore, measurement of 
generally referred to as the Smith-Lemli-Opitz syndrome plasma cholesterol will play a role in the follow-up of
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the cholesterol oxidase method with those of a gas- GC assays. For GC deteimination of cholesterol and its
chromatographic (GC) technique.
Materials and Methods
precursors (7-DHC and 8-DHC), we combined 60 ¡xl of 
plasma with 7.58 nmol of 5/3-cholestane-3a-ol as internal 
standard (no. C5050; Steraloids, Wilton, NH) in 1 mL of a
Patients. We analyzed plasma from eight patients (ages 2 solution of 0.32 mol/L KOH in 95% ethanol. The CFAS-
weeks to 33 years) who had the characteristic clinical calibrator for cholesterol was used (no. 759350; Boehr-
signs and symptoms of SLO. Forty-eight plasma samples, inger Mannheim) in combination with two control sera 
included as a diseased control group, had been sent to our (Precinorm and Precipath; also from Boehringer Mann-
laboratory for metabolic screening; however, the patients heim). After an incubation of 15 min at 55 °C, 1 mL of H20
in this control group did not show clinical signs and and 4 mL 0f pentane were added and mixed for 5 min.
symptoms characteristic for SLO, and some were under The steroidS/ which were extracted into the pentane layer,
special clinical conditions (e.g., feeding problems, meta­
bolic crises, special dietary formulas). This group pro­
vides the background against which metabolic screening 
laboratories have to diagnose patients with SLO. Because 
this study was not devised to obtain reference ranges for 
cholesterol in various age groups, the data presented later 
(in Table 1) should not be considered as such.
Enzymatic assays. Plasma cholesterol was measured at 30 °C 
with an enzymatic test on a Hitachi 747 analyzer (Boehringer 
Mannheim, Mannheim, Germany) according to the in­
structions of the manufacturer and with use of Boehringer 
reagents (CHOD-PAP test; SYS-3:1127578/1489704). In
were taken up by pipetting after centrifugation 
(5000# • min). The pentane was then evaporated with 
nitrogen at -50 °C. To derivatize the steroids, we added 
100 fiL of an equivolume solution of N ,0-bis(trimethylsi- 
lyl)trifluoroacetamide (no. 15238; Fluka, Buchs, Switzer­
land) and pyridine and incubated at 60 °C for 30 min. GG 
analysis was performed with a Hewlett-Packard (Am­
stelveen, The Netherlands) Model 5890 GC and a 25 m X
0.25 mm (i.d.) CP-Sil-19 CB column (film thickness 0.2 
jU,m; Chrompack, Bergen op Zoom, The Netherlands). The 
temperature program was started at 240 °C, increased to 
300 °C at 5 °C/min, and held for 3 min at 300 °C. Tem-
this test, cholesterol and cholesterol esters are converted by peratures of the injector and detector were 280 and 300 °C, 
the sequential action of cholesterol esterase and cholesterol respectively. Pure 7-DHC for calibration purposes was 
oxidase. The H20 2 formed in the latter reaction is deter- purchased from Sigma Chemical Co., St. Louis, MO; no.
mined quantitatively in the last step by using a peroxidase D-3625); to quantify 8-DHC, we used the calibration curve 
that converts phenol and 4-aminophenazone into 4-(p-ben- for 7-DHC because 8-DHC for calibration was not avail-
zoquinone-monoimino)-phenazone. able commercially.
Table 1. Sterol concentrations (#tmol/La) in plasma from patients with Smith-Lemli-Opitz syndrome and
from diseased controls.
■
Gas chromatography
Sex, age
Enzymatic
cholesterol
SLO patient 
1 F, 11 d 700
2 M, 7 m 1000
3 M, 7 y 1820
4 M, 26 y 1560
5 M, 27 y 1300
6 M, 28 y 1700
7 F, 29 y 2080
8 F, 33 y 3800
Range, diseased control group <1 y (12)d 2400-4900
1-5 y (12) 2100-5300
6-15 y (10) 3200-5700
>15 y (14) 2900-8600
Reference intervals for healthy 1-3 y 1150-4700
children® 4-6 y 2800-4800
7-9 y 2900-6400
aTo convert cholesterol from /¿mol/L to mg/dl: 1000 /xmol/L = 38.67 mg/dL. 
b Cholesterol (GC) + 7-DHC (GC) + 8-DHC (GC). 
c [7-DHC (GC) + 8-DHC (GC)]/cholesterol (GC).
6 n for each group is listed in parentheses. 
e 0.025-0.975 fractiles, according to Lockitch et al. [13].
Cholesteroli 7-DHC 8-DHC Total* Ratfoc
20 430 266 716 34.8
260 300 385 945 2.6
975 280 264 1519 0.6
1118 182 127 1427 0.3
884 143 107 1134 0.3
1170 220 284 1674 0.4
1261 442 308 2011 0.6
2030 848 555 3433 0.7
2523-4805 <7 <5 <0.004
2139-5447 <5 <5 <0.003
3138-5775 <5 <5 <0.002
3174-8226 <8 <10 <0.003
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GC-MS. Mass spectra from peaks separated by GC were 
obtained by using a VG Trio 2 quadrupole mass spec­
trometer (Micromass, Altrincham, Cheshire, UK) coupled
to the Hewlett-Packard 5890 GC. The cholesterol peak 
was characterized by fragments at m/z 329, 353, and 458. 
7-DHC and 8-DHC gave identical spectra, with character­
istic fragments at m/z 351 and 456.
Recovery studies. To test whether 7-DHC contributes to the 
result of the enzymatic cholesterol assay, we performed 
recovery experiments for cholesterol and 7-DHC in a 
human serum matrix and in human serum albumin 
solution (Sigma, no. A 16535; 50 g/L in 0.15 mol/L NaCl). 
The sterols, which had been dissolved to 33 mmol/L 
solution in ethanol, were added to both matrices to yield 
final concentrations of 1, 2, and 3 mmol/L. Complete 
solubilization was obtained by adding Nonidet P-40 (no.
mL/L
Results
Enzymatic assay for plasma cholesterol. Table 1 shows the 
plasma cholesterol concentrations obtained with the cho­
lesterol oxidase method for our diseased control group 
and the SLO patients. For the group of SLO patients as a 
whole, the cholesterol concentrations generally were be­
low the concentration range found in the control group. 
However, there was an overlap between values for the 
two groups. One SLO patient (case 8) had a plasma 
cholesterol concentration of 3.8 mmol/L with this test, 
which would be interpreted as a low but normal value for 
an adult. The values found for the SLO children (cases 
1-3) were close to the range found in our diseased control 
group; their diagnosis could easily have been missed if no 
further data had been available.
GC analysis of cholesterol, 7-DHC, and 8-DHC. The gas 
chromatograms of the plasma samples from a patient in 
the diseased control group and from two patients with 
SLO all showed peaks for the internal standard, choles­
terol, 8-DHC, and 7-DHC (Fig. 1). Identification of the 
compounds was based on their retention times and on 
mass spectra (not shown). In agreement with the data 
from Axelson [10], we observed that 7-DHC occurs in 
trace amounts in normal human plasma. Using calibration 
curves for cholesterol, 7-DHC, and the internal standard, 
we confirmed the linearity of the method for the concen­
tration range used in this study (data not shown).
Plasma concentrations of cholesterol measured with
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Fig. 1. Capillary-column gas chromatograms of control plasma (top 
panel) and plasma from two SLO patients (the middle panel shows
Peaks: IS, internal standard (5ß-cholestane-3a-ol); A, cholesterol; S, 8-DHC; and 
C, 7-DHC.
GC vary considerably among SLO patients (20 2030 plasma from patient 1 and the bottom panel plasma from patient 5, 
jumol/L) and also show an overlap in concentrations Table 1).
between the SLO group and the diseased control group, 
similar to the overlap observed in the enzymatic choles­
terol assay. In all patients with SLO, the concentrations of
7-DHC and 8-DHC were clearly increased (GC results, disease. Patients 1 and 2, who had a severe form of the 
Table 1). These data lead to a straightforward diagnosis disease (type 1), gave higher values for this ratio than did 
for all SLO cases in this study. The ratio of (7-DHC + the rest of the SLO group.
8-DHC) / cholesterol may correlate with the severity of the The correlation between the enzymatic assay and the
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Until now, studies on reference values for plasma choles­
terol have focused on the upper limit of the reference 
range: Very few data are available for the lower limit of 
the cholesterol reference range in plasma from children of 
various age groups. Lane and McConathy have studied 
changes in serum cholesterol in the first month of life 
using GC [12]. Lockitch et al. [13] determined age-related 
reference values for serum cholesterol in 450 healthy 
children, ages 1 to 19 years. Plasma cholesterol data in our 
diseased control group are in line with the data of
Lockitch et al. [13]. The 0.025 fractile those authors found 
for the age groups older than 6 years is similar to the 
lowest value found in our diseased control group. For the 
age group between 1 and 5 years, Lockitch et al. found a 
0.025 fractile value of 1.15 mmol/L, whereas the lowest 
value in our diseased control group was 1.67 mmol/L.
Because patients with SLO are often severely affected 
at birth, reference values for plasma cholesterol in the first 
weeks of life are of special interest. Lane and McConathy 
[12] observed that cholesterol at day 28 postpartum ordi­
narily is in the lower 5th percentile of the adult popula­
tion values; at day 3 postpartum, values were even lower 
[12]. Age-related reference values are thus invaluable for 
the correct interpretation of plasma cholesterol concentra-
Fig. 2. Correlation between enzymatic cholesterol oxidase results and tions in children. As Table 1 makes clear, SLO patients
GC results for plasma cholesterol in SLO patients (■) and diseased 
control patients (O).
measured with the enzymatic assay may give plasma 
cholesterol values close to the lower limit of the range of 
the diseased control group or even within this range. In 
GC assay results for plasma cholesterol was good in the one of our adult patients (case 8), the plasma cholesterol 
diseased control group (Fig. 2), the Passing and Bablok concentration of 3.8 mmol/L would be interpreted as 
([11 ]) regression line (and 95% confidence intervals) being normal. We were able to better discriminate between both 
y =  1.02 (0.95-1.08) x — 0.080 (—0.31 to 0.20). In die SLO groups by assessing the cholesterol values measured by 
group, the results of both methods for the plasma samples GC. However, even with this assay, the result for choles-
all deviated from that correlation line, to yield y 0.68 terol could easily be misinterpreted. We conclude that the
(0.37-1.15) x — 0.211 (—0.84 to 0.44). Because the choles- diagnosis of SLO cannot be excluded definitely on the 
terol concentrations found for the SLO group were sys- basis of the plasma cholesterol results.
tematically higher by the enzymatic test than by GC The control samples gave results by both the enzymatic
(Table 1), we hypothesized that 7-DHC and 8-DHC might and the GC method for cholesterol that correlated well 
contribute to the results of the enzymatic cholesterol (Table 1 and Fig. 1). For SLO patients, however, obvious
assay; consequently, we performed recovery experiments 
with cholesterol and 7-DHC.
techniques 
5 measured
Recovery experiments. Cholesterol recovery in the enzy-
assay being invariably higher than the GC results. As
summed
mean recovery
serum matrix
mean in
Most
range
mean in serum ma 
albumin matrix, 7'. 
known instability 
recovery of this cc
Discussion
Reliable quantitative results for cholesterol, 7-DHC, and 
8-DHC are invaluable to confirm the diagnosis in patients 
clinically suspected to have SLO, and for follow-up of 
SLO patients being treated with high-cholesterol diets.
7-DHC, and 8-DHC correlated well with the enzymati- 
9, range 100-120%) and the cally determined cholesterol concentration. This suggests
that 7-DHC and 8-DHC may contribute to the plasma 
cholesterol results measured by the enzymatic cholesterol 
assay. We partly confirmed this by adding 7-DHC to 
solutions of albumin and to plasma samples. The majority
(61—71%) of 7-DHC added was measured as cholesterol by
the enzymatic cholesterol test, in both the serum matrix 
and the human albumin matrix. The results for cholesterol 
measured by GC were not influenced by these additions
o (n = 6, range 5-70%); mean in 
6, range 70-75%). Possibly, the
cannot discriminate 
may be due to asp<
enzymatic
monolayer
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system, Slotte has described that cholesterol oxidase from 
Streptomyces cinnamomeus oxidizes 7-DHC at a rate 5.1- 
fold slower than it oxidizes cholesterol [14]. We expect 
that similar results will be found for other commercially 
available reagents for plasma cholesterol determinations 
that make use of cholesterol oxidase. Our results indicate 
that the enzymatic test for measuring plasma cholesterol 
gives falsely high results for SLO plasma samples.
The plasma cholesterol concentration in our youngest 
patient with SLO was 20 /xmol/ L, whereas the (7-DHC + 
8-DHC) / cholesterol ratio for this patient was by far the 
greatest we saw. This is, to our knowledge, the lowest 
plasma cholesterol ever reported in humans. Clinically, 
the affected girl had a very severe form of the disease 
(type I), with major malformations; the patient died at age 
5 weeks. As also described by Tint et al. [15], we observed 
that the plasma cholesterol concentration in older SLO 
patients is generally higher than in young, more severely 
affected patients. In our study the lowest and the highest 
cholesterol values we saw differed by 20-fold. Those for 
7-DHC differ by only 6-fold, and the concentrations of
7-DHC and 8-DHC are not significantly different between 
younger and older patients in our study. The (7-DHC +
8-DHC) / cholesterol ratio, however, is clearly higher in 
the young patients (cases 1 and 2 in Table 1).
The differences in plasma cholesterol concentrations of 
SLO patients at different ages might result from a higher 
dietary intake of cholesterol in older, clinically more 
mildly affected patients. Kelley et al. have suggested [16] 
that higher cholesterol concentrations correlate more with 
the length of survival and the amount of dietary choles­
terol than with clinical severity. Another explanation for 
higher cholesterol concentrations in older SLO patients 
could be the residual activity of the cholesterol biosynthe­
sis pathway in older patients, as was suggested by Tint et 
al. [15]. This would also explain the milder course of the 
disease in this group. At present, it is unknown whether 
the shortage of cholesterol and the abundance of choles­
terol precursors both contribute to the development of the 
clinical signs and symptoms of SLO. As with cholesterol 
oxidase, other enzymes involved in cholesterol-convert­
ing pathways may also accept a 7-dehydro or 8-dehydro 
variant of their normal substrates. This would give rise to 
unexpected intermediates with unpredictable functional 
characteristics. This concept may give further impetus to 
attempts to understand the importance of cholesterol 
precursors in the development of the clinical picture.
Summarizing, we conclude that the enzymatic test for 
measuring plasma cholesterol gives unreliable results in 
SLO patients. For diagnosis of patients clinically sus­
pected to have the disease, measurements of plasma
cholesterol (by any method) should n o t be used. Obvi­
ously, quantification of plasma 7-DHC and 8-DHC is the 
method of choice here [4, 5,15]. For follow -up studies of 
SLO patients receiving high-cholesterol dietary treatment, 
the enzymatic test for measuring p lasm a cholesterol is 
also not suitable. Instead, the m ethod of choice for this 
purpose may be GC, which provides reliable quantitative 
data for plasma cholesterol, 7-DHC, and 8-DHC.
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